The US Food and Drug Administration (FDA) has approved AbbVie’s Mavyret (glecaprevir and pibrentasvir), the first drug to treat all six genotypes of Hepatitis C virus (HCV), for children with the condition aged between 12 and 17.
The label for Eli Lilly and Company's once-weekly Trulicity® (dulaglutide) is now updated to include use in combination with basal insulin for adults with type 2 diabetes.